Longevity & Mitochondrial · Research deep dive
SS-31: the cited literature
Every study referenced in the SS-31 monograph, with plain-language context, PubMed links to read each paper yourself, and how the compound appears in the dosing literature.
How this compound is studied
Across the dosing literature, SS-31 is studied at 2.5 mg – 5 mg per administration, typically once daily. The reference walkthrough below maps each citation to what it actually showed.
References covered
Elamipretide in primary mitochondrial myopathy (MMPOWER-3)
Neurology, 2022
The full walkthrough is for subscribers
Unlock the evidence grading, what each study actually found, how the trials dosed it, reported safety signals, open questions, and PubMed links for SS-31.